文献速递肝病消化道肿瘤与早癌

TACE扰乱肠道菌群代谢加重肝细胞癌术后肝损伤

Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC.
PubMed 文献 · J Hepatol · 2025-10-17

本研究探讨经动脉化疗栓塞(TACE)后肝损伤(TACE-LI)与肠道菌群紊乱的关系。大鼠及患者粪便移植实验显示,菌群耗竭或接受TACE供体粪菌移植的大鼠TACE-LI更严重;TACE后罗伊氏粘液乳杆菌(L. reuteri)及其代谢物吲哚-3-乳酸(ILA)减少,补充L. reuteri或ILA可减轻TACE-LI。

要点

  • TACE后L. reuteri丰度及ILA水平降低与肝损伤加重和总生存期较差相关。
  • L. reuteri依赖苯乳酸脱氢酶生成ILA,ILA抑制HSP90 ATP酶活性并失活巨噬细胞NLRP3炎症小体。
  • 补充L. reuteri或ILA可保护大鼠免受TACE-LI,或为有前景的治疗策略。

核心结论

  • 肠道菌群紊乱即L. reuteri代谢物ILA缺乏是TACE-LI的重要病因,补充L. reuteri或ILA可减轻TACE相关不良反应并改善预后。

研究设计与样本

  • 采用微生物多组学分析、基因工程菌和转录组学研究TACE-LI中的菌群紊乱与宿主反应。
  • 使用抗生素清除肠道菌群的大鼠及接受TACE供体大鼠或患者粪菌移植的大鼠进行实验。

主要发现

  • 抗生素清除菌群大鼠及接受TACE供体粪菌移植大鼠表现出更严重的TACE-LI。
  • TACE处理大鼠和HCC患者中L. reuteri丰度显著降低,TACE后L. reuteri减少导致色氨酸代谢物ILA水平下降。
  • 给予活L. reuteri或ILA可有效保护免受TACE-LI。
  • L. reuteri依赖关键酶苯乳酸脱氢酶生成ILA,ILA抑制热休克蛋白90的ATP酶活性,从而失活巨噬细胞NOD样受体蛋白3炎症小体并抑制肝脏促炎反应。
  • L. reuteri和ILA水平降低与TACE治疗的HCC患者肝损伤加重和总生存期较差相关。

临床怎么用

  • 补充L. reuteri或ILA可能作为减轻TACE相关不良反应并改善HCC预后的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Transarterial chemoembolization (TACE) is widely used to treat unresectable hepatocellular carcinoma (HCC). Liver injury induced by TACE (TACE-LI) is the most common complication and limits long-term outcomes. Beyond the conventional understanding of direct TACE-induced damage to normal liver tissue, the underlying mechanisms of TACE-LI remain unclear. We aimed to elucidate the relationship between gut microbiota disturbances and TACE-LI. METHODS: Microbial multi-omics analysis, genetically engineered bacteria and transcriptomics were used to study microbiota disturbances and host responses in TACE-LI. RESULTS: Rats with antibiotic-depleted gut microbiota, as well as rats receiving fecal transplants from donor rats or patients who had undergone TACE, exhibited more severe TACE-LI. Limosilactobacillus reuteri (L. reuteri) abundance was significantly reduced in TACE-treated rats and patients with HCC. Reduced L. reuteri abundance after TACE led to decreased levels of tryptophan metabolite indole-3-lactic acid (ILA), while administration of live L. reuteri or ILA provided effective protection against TACE-LI. Mechanistically, L. reuteri relied on the key enzyme phenyllactate dehydrogenase to generate ILA. ILA inhibits the ATPase activity of heat shock protein 90, thereby deactivating the NOD-like receptor protein 3-inflammasome in macrophages and suppressing hepatic pro-inflammatory responses. Reduced levels of L. reuteri and ILA were correlated with aggravated LI and poorer overall survival in TACE-treated patients with HCC. CONCLUSIONS: This is the first study to identify gut microbiota disturbance, i.e. deficiency of L. reuteri metabolite ILA, as a significant cause of TACE-LI. Administration of L. reuteri or ILA may serve as a promising therapeutic strategy to mitigate TACE-related adverse effects and improve prognosis in HCC. IMPACT AND IMPLICATIONS: Transarterial chemoembolization (TACE) is widely used to treat unresectable hepatocellular carcinoma (HCC), but its long-term outcomes are limited by liver injury (LI). Beyond direct ischemic- or chemotherapy-induced liver damage, the mechanisms underlying TACE-induced LI (TACE-LI) remain unclear. We found that TACE disturbs the gut microbiota, notably reducing levels of Limosilactobacillus reuteri (L. reuteri) and its metabolite indole-3-lactic acid (ILA). These reductions were associated with aggravated TACE-LI and poorer overall survival in patients with HCC. Administration of L. reuteri or ILA significantly alleviated TACE-LI by suppressing macrophage-driven inflammation. This study is the first to identify gut microbiota disturbances as a key contributor to TACE-LI. Supplementing L. reuteri or ILA represents a safe and promising strategy to prevent TACE-LI, reduce TACE-related adverse effects, and improve prognosis in patients with HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Li R, Liu J, Ye F, et al. Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC. J Hepatol. 2025. PMID: 41110523. doi:10.1016/j.jhep.2025.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。